Company Team Projects Media Contact


Investing in biomedical discoveries

LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.




Combioxin reports positive meeting with EMA Innovation Task Force on CAL02 clinical development plan. November 12, 2019

LASCCO's portofolio company Combioxin's CAL02 ranked medical breakthrough - Results of the CAL02 first-in-human trial published by The Lancet Infectious Diseases. May 2, 2019